Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
Atypical adenomatous hyperplasia (AAH) is a putative precursor of bronchioloalveolar carcinoma (BAC) and adenocarcinoma of the lung, developing from terminal respiratory unit cells. AAH and BAC lesions typically present as ground-glass opacities at spiral chest computed tomography. Epidermal growth factor receptor polysomy/mutations, conferring higher sensitivity to Gefitinib, are frequent in BAC but less common in AAH. We describe an interesting case of disseminated AAH showing a sustained remission under Gefitinib therapy.
Pastorino
Ugo
U
Department of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. ugo.pastorino@istitutotumori.mi.it
Calabrò
Elisa
E
Tamborini
Elena
E
Marchianò
Alfonso
A
Orsenigo
Marta
M
Fabbri
Alessandra
A
Sozzi
Gabriella
G
Novello
Silvia
S
De Marinis
Filippo
F
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D006801:Humans; D006965:Hyperplasia; D008168:Lung / Q000473:pathology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D016133:Polymerase Chain Reaction; D011799:Quinazolines / Q000627:therapeutic use*; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib